Chlordiazepoxide (original) (raw)

Explore a selection of our essential drug information below, or:

Summary

Chlordiazepoxide is a benzodiazepine used to treat the withdrawal symptoms of acute alcoholism, to treat preoperative anxiety, and to treat anxiety over a short term period.

Brand Names

Chlorax, Librax

Generic Name

Chlordiazepoxide

DrugBank Accession Number

DB00475

Background

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

Type

Small Molecule

Groups

Approved, Illicit, Investigational

Structure

Weight

Average: 299.755
Monoisotopic: 299.082539792

Chemical Formula

C16H14ClN3O

Synonyms

Indication

Chlordiazepoxide is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.8

In combination with amitriptyline, chlordiazepoxide is indicated for the treatment of moderate to severe depression.7 In combination with clidinium, chlordiazepoxide is indicated to control emotional and somatic factors in gastrointestinal disorders, and is used as adjunctive therapy in the treatment of peptic ulcer, irritable bowel syndrome and acute enterocolitis.6

Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.

Associated Conditions

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API

Pharmacodynamics

Chlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.

Mechanism of action

Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor. BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.

Target Actions Organism
AGABA(A) Receptor positive allosteric modulator Humans
AGABA(A) Receptor Benzodiazepine Binding Site ligand Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Route of elimination

Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.

Half-life

24-48 hours

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.

Toxicity

LD50=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with 1,2-Benzodiazepine.
Acetazolamide The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Acetazolamide.
Acetophenazine The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Acetophenazine.
Agomelatine The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Agomelatine.
Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlordiazepoxide.

Food Interactions

Drug product information from 10+ global regionsOur datasets provide approved product information including: dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.

Product Ingredients

Ingredient UNII CAS InChI Key
Chlordiazepoxide hydrochloride MFM6K1XWDK 438-41-5 DMLFJMQTNDSRFU-UHFFFAOYSA-N

Product Images

International/Other Brands

Angirex / Elenium (Polfa Tarchomin) / Helogaphen / Klopoxid (Nycomed) / Libritabs / Multum / Napoton / Radepur (AWD) / Risolid (Actavis) / Silibrin / Sonimen / Tropium

Brand Name Prescription Products

Generic Prescription Products

Mixture Products

Unapproved/Other Products

ATC Codes

N05BA02 — Chlordiazepoxide

Drug Categories

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzodiazepines

Sub Class

1,4-benzodiazepines

Direct Parent

1,4-benzodiazepines

Alternative Parents

Imidolactams / Benzene and substituted derivatives / Aryl chlorides / Nitrones / Propargyl-type 1,3-dipolar organic compounds / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic zwitterions / Organic oxides / Hydrocarbon derivatives show 2 more

Substituents

1,4-benzodiazepine / Allyl-type 1,3-dipolar organic compound / Amidine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Carboxylic acid amidine / Hydrocarbon derivative / Imidolactam / Monocyclic benzene moiety / Nitrone / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic zwitterion / Organochloride / Organohalogen compound / Organonitrogen compound / Organopnictogen compound / Propargyl-type 1,3-dipolar organic compound show 13 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

organochlorine compound, secondary amino compound, N-oxide, benzodiazepine (CHEBI:3611)

Affected organisms

UNII

6RZ6XEZ3CR

CAS number

58-25-3

InChI Key

ANTSCNMPPGJYLG-UHFFFAOYSA-N

InChI

InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)

IUPAC Name

7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-ium-4-olate

SMILES

CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1

Synthesis Reference

Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.

General References

  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [Article]
  2. Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. [Article]
  3. Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [Article]
  4. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Article]
  5. Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [Article]
  6. FDA Approved Drug Products: Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsules for oral use [Link]
  7. FDA Approved Drug Products: LIMBITROL (chlordiazepoxide and amitriptyline HCI) double strength tablets [Link]
  8. DailyMed Label: Chlordiazepoxide hydrochloride Oral Capsules [Link]

External Links

Human Metabolome Database

HMDB0014618

KEGG Drug

D00267

PubChem Compound

2712

PubChem Substance

46505044

ChemSpider

10248513

BindingDB

50007664

RxNav

2356

ChEBI

3611

ChEMBL

CHEMBL451

ZINC

ZINC000019632917

Therapeutic Targets Database

DAP000084

PharmGKB

PA448932

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Chlordiazepoxide

MSDS

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more.

Preview package

Manufacturers

Packagers

Dosage Forms

Form Route Strength
Capsule Oral 10 mg
Tablet, sugar coated Oral 5 mg
Capsule Oral 25 mg
Capsule Oral 5 mg
Tablet Oral
Tablet, film coated Oral
Capsule Oral
Capsule Oral 10 mg/1
Capsule Oral 25 mg/1
Capsule Oral 5 mg/1
Capsule, gelatin coated Oral
Tablet, film coated Oral 5 mg
Tablet
Tablet, coated Oral
Capsule Oral 10 mg / cap
Capsule Oral 25 mg / cap
Pill
Tablet, sugar coated Oral 5 mg
Tablet, film coated
Pill Oral
Tablet, coated Oral
Tablet, sugar coated Oral
Capsule, gelatin coated Oral 10 mg/1
Capsule, gelatin coated Oral 25 mg/1
Capsule, gelatin coated Oral 5 mg/1
Tablet, film coated Oral 25 MG
Capsule Oral 5 mg / cap
Capsule Oral
Solution / drops

Prices

Unit description Cost Unit
Librax 2.5-5 mg capsule 6.5USD capsule
Librax capsule 5.78USD capsule
Librium 25 mg capsule 2.14USD capsule
Limbitrol DS 10-25 mg tablet 1.93USD tablet
Librium 10 mg capsule 1.61USD capsule
Librium 5 mg capsule 0.84USD capsule
Chlordiazepoxide 25 mg capsule 0.72USD capsule
ChlordiazePOXIDE HCl 25 mg capsule 0.32USD capsule
ChlordiazePOXIDE HCl 10 mg capsule 0.31USD capsule
ChlordiazePOXIDE HCl 5 mg capsule 0.31USD capsule
Chlordiazepoxide 5 mg capsule 0.2USD capsule
Apo-Chlordiazepoxide 25 mg Capsule 0.17USD capsule
Chlordiazepoxide 10 mg capsule 0.14USD capsule
Apo-Chlordiazepoxide 10 mg Capsule 0.11USD capsule
Apo-Chlordiazepoxide 5 mg Capsule 0.07USD capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

State

Solid

Experimental Properties

Property Value Source
melting point (°C) 236-236.5 Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.
water solubility 2000 mg/L YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP 2.44 HANSCH,C ET AL. (1995)
pKa 4.8 MERCK INDEX (1996)

Predicted Properties

Property Value Source
Water Solubility 0.0199 mg/mL ALOGPS
logP 2.01 ALOGPS
logP 0.19 Chemaxon
logS -4.2 ALOGPS
pKa (Strongest Acidic) -2.7 Chemaxon
pKa (Strongest Basic) 7.06 Chemaxon
Physiological Charge 1 Chemaxon
Hydrogen Acceptor Count 3 Chemaxon
Hydrogen Donor Count 1 Chemaxon
Polar Surface Area 50.46 Å2 Chemaxon
Rotatable Bond Count 1 Chemaxon
Refractivity 87.34 m3·mol-1 Chemaxon
Polarizability 31.22 Å3 Chemaxon
Number of Rings 3 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule No Chemaxon

Predicted ADMET Features

Property Value Probability
Human Intestinal Absorption + 1.0
Blood Brain Barrier + 0.9758
Caco-2 permeable + 0.5868
P-glycoprotein substrate Substrate 0.6705
P-glycoprotein inhibitor I Non-inhibitor 0.521
P-glycoprotein inhibitor II Non-inhibitor 0.7434
Renal organic cation transporter Non-inhibitor 0.5502
CYP450 2C9 substrate Non-substrate 0.6991
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Substrate 0.7408
CYP450 1A2 substrate Inhibitor 0.7564
CYP450 2C9 inhibitor Non-inhibitor 0.6038
CYP450 2D6 inhibitor Non-inhibitor 0.7862
CYP450 2C19 inhibitor Non-inhibitor 0.5
CYP450 3A4 inhibitor Inhibitor 0.7067
CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6372
Ames test Non AMES toxic 0.593
Carcinogenicity Non-carcinogens 0.7108
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.8520 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9198
hERG inhibition (predictor II) Non-inhibitor 0.8828

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Mass Spec (NIST)

Not Available

Spectra

Spectrum Spectrum Type Splash Key
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0ce9-3190000000-fd85fc0a63c0f6fa743a
GC-MS Spectrum - CI-B GC-MS splash10-0udi-0079000000-a3045f81d776a5127fe9
GC-MS Spectrum - EI-B GC-MS splash10-001i-5590000000-a20477457b7e9f8a22ea
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-001i-0090000000-a293b353926a16c4d11a
MS/MS Spectrum - , positive LC-MS/MS splash10-004i-2590000000-965415c5fb9e79098c6d
Predicted 1H NMR Spectrum 1D NMR Not Applicable
Predicted 13C NMR Spectrum 1D NMR Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source
[M-H]- 172.553974 predicted DarkChem Lite v0.1.0
[M-H]- 165.91515 predicted DeepCCS 1.0 (2019)
[M+H]+ 173.028374 predicted DarkChem Lite v0.1.0
[M+H]+ 168.27315 predicted DeepCCS 1.0 (2019)
[M+Na]+ 172.533774 predicted DarkChem Lite v0.1.0
[M+Na]+ 174.87038 predicted DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock new insights and accelerate drug research.Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Kind

Protein group

Organism

Humans

Pharmacological action

Yes

Actions

Positive allosteric modulator

The GABA(A) receptor is pentameric (i.e. comprising 5 subunit proteins) and therefore has a multitude of potential isoforms. The above target is a collection of all possible GABA(A) subunits that may participate in the formation of the pentameric receptor and is not meant to imply direct a drug-protein interaction for each individual subunit.

General Function

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity).

Specific Function

GABA-A receptor activity


Components:
References
  1. Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]
  2. Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]

Kind

Protein group

Organism

Humans

Pharmacological action

Yes

Actions

Ligand

Benzodiazepines modulate GABA(A) function by binding at the interface between alpha (α) and gamma (γ) subunits. Of the 6 α-subunits, only 4 (α-1, -2, -3, and -5) participate in the formation of this binding site. The above target is a collection of all α- and γ-subunits that are known to participate in the formation of the benzodiazepine binding site.

General Function

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity).

Specific Function

GABA-A receptor activity


Components:
References
  1. Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]
  2. Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]

Enzymes

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Substrate

General Function

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981).

Specific Function

1,8-cineole 2-exo-monooxygenase activity

Gene Name

CYP3A4

Uniprot ID

P08684

Uniprot Name

Cytochrome P450 3A4

Molecular Weight

57342.67 Da

References
  1. Stolbach A, Paziana K, Heverling H, Pham P: A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. J Med Toxicol. 2015 Sep;11(3):326-41. doi: 10.1007/s13181-015-0465-0. [Article]

Drug created at June 13, 2005 13:24 / Updated at October 01, 2024 12:45